AusBiotech proudly celebrates the outstanding achievements of Professor David Thomas, the founder and chief Science and strategy officer of the not-for-profit genomics organisation Omico, an AusBiotech member, and the director of the Centre for Molecular Oncology at UNSW, who has been honoured with NSW’s highest recognition for cancer research at the NSW Premier’s Awards for Outstanding Cancer Research.
The Outstanding Cancer Researcher of the Year Award recognises significant contributions to cancer research in NSW, with lasting impacts on patient outcomes and a commitment to advancing the state’s research capacity through leadership and mentorship.
“Receiving this award is a great honour and also recognises the importance of precision oncology as an indispensable tool in our fight against cancer,” said Professor Thomas.
“Genomics and precision oncology is no longer a distant vision; it’s a mature, evidence-based approach here and now, that is evolving the way we can assess and treat cancers. Our challenge is to ensure every Australian patient, wherever they are, can benefit from this tailored approach.”
“New South Wales provides an outstanding environment for this endeavour, with its world-class research infrastructure, commitment to innovation, and vibrant clinical community. I congratulate the State Government for recognising commitment to the life science sector not only saves lives; it also creates jobs, forms healthcare networks and supports economic growth,” added Professor Thomas
Rebekah Cassidy, CEO of AusBiotech, praised Professor Thomas’s profound impact on cancer research.
“Professor David Thomas is a visionary leader in genomic cancer medicine, whose work has not only transformed outcomes for patients but has also positioned Australia as a global leader in precision oncology. His contributions reflect the best of what our life sciences sector offers: world-class research, clinical excellence, and unwavering commitment to improving patient lives," said Ms Cassidy.